Outcomes of patients with relapsed low-grade lymphoma retreated with rituximab are similar to rituximab naïve patients.
Leuk Lymphoma. 2019 Apr 18;:1-4
Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin's lymphoma: an international, multicentre, single-arm, phase 1-2 trial.
Lancet Oncol. 2018 02;19(2):257-266
Mobilization of leukemic cells using plerixafor as part of a myeloablative preparative regimen for patients with AML undergoing allografting: assessment of safety and tolerability.
Biol Blood Marrow Transplant. 2019 Jan 14;:
Brentuximab Vedotin Plus Chemotherapy in North American Patients with Newly Diagnosed Stage III or IV Hodgkin Lymphoma.
Clin Cancer Res. 2019 Jan 07;:
Expert Rev Hematol. 2018 Oct 19;:
A phase I study of romidepsin, gemcitabine, dexamethasone and cisplatin combination therapy in the treatment of peripheral T-cell and diffuse large B-cell lymphoma; the Canadian cancer trials group LY.15 study†.
Leuk Lymphoma. 2018 Oct 10;:1-8
Significance of treatment response when managing patients with primary central nervous system lymphoma.
Leuk Lymphoma. 2018 Jul 03;:1-9
Zinc Finger Protein 521 regulates early hematopoiesis through cell extrinsic mechanisms in the bone marrow microenvironment.
Mol Cell Biol. 2018 Jun 18;:
A phase IV, randomized, multicenter, open-label trial comparing efficacy and systemic exposure for a standard weight-based dose versus a fixed dose of plerixafor in combination with G-CSF in patients with Non-Hodgkin's lymphoma weighing ≤70 kg.
Bone Marrow Transplant. 2018 Jun 12;: